Galina Obmolova is a prominent inventor based in Spring House, Pennsylvania, known for her significant contributions to the field of antibody research. With a total of 13 patents to her name, she has made remarkable strides in developing innovative solutions for medical challenges.

Latest Patents

Among her latest patents is the invention of neutralizing human anti-CD27 antibodies. These human antibodies are designed to block the binding of CD27 to its ligand CD70, effectively neutralizing the bioactivity of CD27. This includes inhibiting CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, and alleviating antibody responses. Additionally, her work addresses the stimulation of tumor cells by CD70 and the production of soluble mediators from T and B-cells. These antibodies hold promise for diagnosing and treating diseases associated with CD27 activity. Another notable patent involves nucleic acids encoding anti-CD154 antibodies, which are antagonistic antibodies that specifically bind to CD154. This invention includes polynucleotides encoding the antibodies or fragments, along with methods for their production and use.

Career Highlights

Galina Obmolova is currently associated with Janssen Biotech, Inc., where she continues to advance her research in antibody development. Her work has been instrumental in pushing the boundaries of what is possible in therapeutic applications.

Collaborations

She has collaborated with notable colleagues, including Johan Fransson and Alexey Teplyakov, contributing to a dynamic research environment that fosters innovation.

Conclusion

Galina Obmolova's contributions to antibody research exemplify her dedication to advancing medical science. Her innovative patents and collaborative efforts position her as a leading figure in the field.

This text is generated by artificial intelligence and may not be accurate.